深圳信立泰药业股份有限公司关于SAL0140 获得临床试验批准通知书的公告

Core Viewpoint - Shenzhen Xinlitai Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0140, aimed at treating chronic kidney disease (CKD) [1][2]. Group 1: Drug Development - SAL0140 is a proprietary aldosterone synthase inhibitor developed by the company, targeting conditions such as uncontrolled hypertension (including resistant hypertension), primary aldosteronism, and chronic kidney disease (CKD) [1]. - The drug is expected to mitigate end-organ damage by inhibiting aldosterone synthesis, which plays a crucial role in maintaining fluid and electrolyte balance and is involved in various cardiovascular and renal diseases [1]. Group 2: Market Potential - If successfully developed and approved, SAL0140 could provide new treatment options for patients in specific subfields, addressing unmet clinical needs and enriching the company's pipeline of innovative products in the chronic disease sector [2]. - The company will conduct clinical trials in accordance with national drug registration regulations, and upon successful trials, will proceed with the registration application [2].